Literature DB >> 7002065

Clotrimazole in rheumatoid arthritis.

J A Wojtulewski, P J Gow, J Walter, R Grahame, T Gibson, G S Panayi, J Mason.   

Abstract

Forty-seven patients with active rheumatoid arthritis took part in an 8-week controlled study in which clotrimazole was compared with a standard nonsteroidal anti-inflammatory agent, ketoprofen. Although clotrimazole was shown to be effective in the treatment of the disease and superior to ketoprofen in certain measurements, if was also responsible for a high incidence of adverse effects. Improvement with clotrimazole took place more slowly but was more sustained than with ketoprofen. A significant rise in plasma cortisol and a fall in white cell count was observed in the clotrimazole treated patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002065      PMCID: PMC1000587          DOI: 10.1136/ard.39.5.469

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

2.  Orudis in management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin.

Authors:  A N Gyory; M Bloch; H C Burry; R Grahame
Journal:  Br Med J       Date:  1972-11-18

3.  Double-blind cross-over study of Orudis and placebo in fifty patients with rheumatoid arthritis.

Authors:  D W Zutshi; S Marr; M Bloch; R M Mason
Journal:  Rheumatol Rehabil       Date:  1973-05

4.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

5.  Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.

Authors:  P L Boardman; F D Hart
Journal:  Br Med J       Date:  1967-11-04

6.  Nitro-imidazole in rheumtoid arthritis.

Authors:  H Abd-Rabbo; H Abaza; G Hillal; M Moghazy; L Asser
Journal:  J Trop Med Hyg       Date:  1972-03

7.  Letter: Clotrimazole and rheumatoid arthritis.

Authors:  R Wyburn-Mason
Journal:  Lancet       Date:  1976-02-28       Impact factor: 79.321

8.  Letter: Clotrimazole and rheumatoid arthritis.

Authors:  I G Otterness; J F Niblack
Journal:  Lancet       Date:  1976-01-17       Impact factor: 79.321

9.  Immunostimulant therapy with levamisole for rheumatoid arthritis.

Authors:  E C Huskisson; J Scott; H W Balme; P A Dieppe; J Trapnell; D A Willoughby
Journal:  Lancet       Date:  1976-02-21       Impact factor: 79.321

  9 in total
  13 in total

Review 1.  Molecular properties and physiological roles of ion channels in the immune system.

Authors:  M D Cahalan; H Wulff; K G Chandy
Journal:  J Clin Immunol       Date:  2001-07       Impact factor: 8.317

Review 2.  K+ channels as targets for specific immunomodulation.

Authors:  K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

3.  The antifungal antibiotic, clotrimazole, inhibits Cl- secretion by polarized monolayers of human colonic epithelial cells.

Authors:  P A Rufo; L Jiang; S J Moe; C Brugnara; S L Alper; W I Lencer
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

Review 4.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

5.  Functional KCa3.1 K+ channels are required for human lung mast cell migration.

Authors:  G Cruse; S M Duffy; C E Brightling; P Bradding
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

6.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

7.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

8.  The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.

Authors:  Kazuyoshi Toyama; Heike Wulff; K George Chandy; Philippe Azam; Girija Raman; Takashi Saito; Yoshimasa Fujiwara; David L Mattson; Satarupa Das; James E Melvin; Phillip F Pratt; Ossama A Hatoum; David D Gutterman; David R Harder; Hiroto Miura
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

Review 9.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

10.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.